MODERATE-TO-SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE-TO-SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot could tame tough eczema in phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called SHR-1905 for adults with moderate-to-severe atopic dermatitis (eczema). About 75 participants will receive either the drug or a placebo injection to see if it safely reduces skin redness, itching, and rash. The main goal is to check if…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
New shot could tame tough eczema in adults
Disease control Recruiting nowThis study tests an experimental drug called SHR-1819 in 200 adults with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it can reduce skin redness, itching, and rash. Participants will receive either the drug or a placebo injection, and researchers…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
New eczema drug TRB-061 enters first human safety trials
Symptom relief Recruiting nowThis study tests an experimental drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as injections under t…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: TRex Bio, Inc. • Aim: Symptom relief
Last updated May 17, 2026 05:35 UTC
-
New eczema drug SYX-5219 enters first human safety trials
Symptom relief Recruiting nowThis early-stage study tests a new drug called SYX-5219 in healthy people and those with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the body processes the drug. Up to 149 participants will receive either the drug or a placebo over seve…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE1 • Sponsor: Sitryx Therapeutics Ltd • Aim: Symptom relief
Last updated May 17, 2026 05:34 UTC